Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine.
D000293:Adolescent; D000328:Adult; D001590:Benztropine / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects; D002395:Catecholamines / Q000037:antagonists & inhibitors / Q000378:metabolism; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008781:Methyltyrosines / Q000627:therapeutic use*; D010830:Physostigmine / Q000627:therapeutic use; D010919:Placebos; D011955:Receptors, Drug; D012075:Remission, Spontaneous; D012601:Scopolamine / Q000627:therapeutic use; D013747:Tetrabenazine / Q000627:therapeutic use*; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000378:metabolism
D002395:Catecholamines; D008781:Methyltyrosines; D010919:Placebos; D011955:Receptors, Drug; D001590:Benztropine; D010830:Physostigmine; D012601:Scopolamine; D004298:Dopamine; D013747:Tetrabenazine